![GNI Group Ltd. logo](/logos/2160.T.webp)
GNI Group Ltd.
TSE:2160.T
Overview | Financials
Company Name | GNI Group Ltd. |
Symbol | 2160.T |
Currency | JPY |
Price | 2,095 |
Market Cap | 104,875,017,030 |
Dividend Yield | 0% |
52-week-range | 1,537 - 3,865 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ying Luo Ph.D. |
Website | https://www.gnipharma.com |
An error occurred while fetching data.
About GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD